Project Grant HT94252510936
Award Date 8/15/25
Completion Date 8/14/28
Dollars Obligated $859K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Charlottesville, VA, USA
Similar Awards
- The Rector & Visitors of the University of Virginia (UVA) was awarded a $1,528,632 Project Grant by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on August 15, 2025, supports research to understand how melanoma-cognate T-cell help enhances survival with melanoma vaccines. The research, to be conducted in Charlottesville, VA, aims to transform healthcare for military service members, veterans, and the public by...
- This Project Grant award, valued at $638,260.00, was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the Rector & Visitors of the University of Virginia (UVA). The funding supports research to investigate "LINKING GENETIC, METABOLIC, AND MICROENVIRONMENTAL PREDICTORS OF MELANOMA METASTATIC COLONIZATION" over the project period of September 1, 2025 to August 31, 2027. UVA, a prominent public research university,...
- The University of Virginia received a $921,351 project grant award on September 30, 2023 from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to support research on "APPROACHES TO ENHANCE VACCINE-INDUCED TUMOR-INFILTRATING LYMPHOCYTES (VITILS) IN MELANOMA". This multi-year grant, scheduled for completion on September 29, 2026, aims to advance biomedical research that can transform healthcare for Service Members and the American public. The...
- This $693,642 federal Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports research at the University of Virginia to enhance vaccine-induced tumor-infiltrating lymphocytes (VITILS) in melanoma. The 3-year research project aims to develop innovative approaches to boost the effectiveness of cancer immunotherapies by improving the ability of T cells to infiltrate and attack melanoma tumors. Key deliverables will include...
- This $646,252 Project Grant award from the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420) supports research to uncover cell intrinsic and extrinsic factors governing melanoma dormancy at single-cell resolution. The primary awardee, Trustees of Boston University, will conduct this advanced biomedical research. The University of Virginia will provide academic and technical resources, including experiments generating and validating...
- The Defense Health Agency awarded a $847,875 Project Grant to the Rector & Visitors of the University of Virginia (UVA) under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "Targeting Schwann Cell-Tumor Microenvironment Interactions in Neurofibroma Development," supports advanced biomedical research to transform healthcare for military service members, veterans, and the public. The research project at UVA aims to investigate the cellular...
- The Department of Defense's Defense Health Agency awarded a $558,832 Project Grant to Tufts University School of Medicine under the Military Medical Research and Development program (CFDA 12.420) on September 30, 2024. This grant will support research focused on "Targeting Differentiation Epitope in CD11b of Tumor-Associated Inflammatory Monocytes: A Novel Adjuvant Dendritic Cell Therapy Approach for Mucosal Melanoma." The research aims to develop an innovative dendritic cell-based...
- The federal Project Grant award of $1,008,313 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. This award supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. The award was granted to The Regents of the University of California, San Francisco (UCSF), a prominent academic medical center and research institution, to conduct research on melanoma....
- This Project Grant award, titled "OVERCOMING IMMUNOTHERAPY RESISTANCE IN ACRAL MELANOMA", is provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The $1,183,560 award to the University of Pittsburgh will support advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. The research project, running from September 1, 2025 to August 31, 2028, will focus on...
- The Defense Health Agency awarded a $1,592,860 Project Grant to the Rector & Visitors of the University of Virginia (UVA) on January 1, 2025 under the Military Medical Research and Development program (CFDA 12.420). The grant will support UVA's research to develop ultrasensitive proteomics techniques for predicting and assessing treatment efficacy for type 1 diabetes. This work aims to transform healthcare for military service members and the broader public by advancing innovative biomedical...